SCHEMBL5864063

SCHEMBL5864063

Nc1ccc2cnn(Cc3cccnc3)c(=O)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
PKM P14618 2/20 0.51
TDP1 Q9NUW8 1/20 0.46
ADORA2A P29274 2/20 0.44
ADORA1 P30542 1/20 0.44
AURKA O14965 2/20 0.43
AURKB Q96GD4 1/20 0.43
GRK2 P25098 1/20 0.43
ROCK1 Q13464 1/20 0.43
RPS6KA1 Q15418 1/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
ALOX5 P09917 1/20 0.42
KDM4E B2RXH2 1/20 0.40
UBE2N P61088 1/20 0.40
ATM Q13315 1/20 0.40
LMNA P02545 1/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
CHRM1 P11229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863967 0.87 TDP1 (0.56) ALDH1A1PKMTDP1AURKAGRK2
SCHEMBL9146392 0.86 PKM (0.53) ALDH1A1PKMTDP1AURKAAURKB
SCHEMBL5864274 0.82 PDE5A (0.43) ALDH1A1TDP1PTGS1PTGS2KDM4E
SCHEMBL31661532 0.80 ALDH1A1 (0.55) ALDH1A1PKMADORA2AADORA1EGFR
SCHEMBL3319079 0.80 ALDH1A1 (0.55) ALDH1A1PKMADORA2AADORA1EGFR
SCHEMBL9145645 0.79 NPBWR1 (0.47) PKMTDP1AURKAGRK2ROCK1
SCHEMBL5863900 0.79 ALDH1A1 (0.47) ALDH1A1PKMTDP1AURKAAURKB
SCHEMBL5864447 0.77 LMNA (0.47) ALDH1A1PKMTDP1LMNAEGFR
SCHEMBL28899162 0.76 NPBWR1 (0.56) ALDH1A1PKMTDP1AURKAGRK2
SCHEMBL25468296 0.74 TDP1 (0.42) ALDH1A1PKMTDP1ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC ALDH1A1 1345/4885PKM 2849/4885TDP1 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.